Source:http://linkedlifedata.com/resource/pubmed/id/15196302
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2004-6-15
|
pubmed:abstractText |
Glutamatergic hyperactivity is implicated migraine pathogenesis. Also, LY293558, an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate (KA) receptor antagonist, is effective in preclinical models of migraine. We therefore tested LY293558 in acute migraine. We conducted a randomized, triple-blind, parallel-group, double-dummy, multicentre trial of 1.2 mg/kg intravenous (IV) LY293558, 6 mg subcutaneous (SC) sumatriptan, or placebo in the treatment of acute migraine. The primary efficacy variable was the headache response rate, i.e. headache score improvement from moderate/severe at baseline to mild/none at 2 h. Of 45 enrolled patients, 44 patients (20M:24F; mean age +/- SD = 40 +/- 9 years) completed the study. Response rates were 69% for LY293558 (P = 0.017 vs. placebo), 86% for sumatriptan (P < 0.01 vs. placebo) and 25% for placebo. LY293558 and sumatriptan were superior to placebo (P < 0.01 for all comparisons) on all other measures of improvement in pain and migraine associated symptoms. Fifteen percent of patients who took LY293558 reported adverse events (AEs) (n = 2; one mild, one severe). Fifty-three percent of patients who took sumatriptan (n = 8; seven mild, one moderate) and 31% of those who received placebo reported AEs (n = 5; four mild, one severe). The efficacy and safety results of LY293558 in this small migraine proof of concept trial, together with supportive preclinical data, provide evidence for a potential role of nonvasoactive AMPA/KA antagonists in treating migraine. Larger trials are needed to further test the hypothesis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Gluk1 kainate receptor,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, AMPA,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Kainic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/tezampanel
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0333-1024
|
pubmed:author |
pubmed-author:ArnoldBB,
pubmed-author:BleakmanDD,
pubmed-author:ChappellA SAS,
pubmed-author:FreitagF GFG,
pubmed-author:JohnsonK WKW,
pubmed-author:OrnsteinP LPL,
pubmed-author:PhebusL ALA,
pubmed-author:RamadanN MNM,
pubmed-author:SangC NCN,
pubmed-author:SilbersteinS DSD,
pubmed-author:SmithT RTR,
pubmed-author:TepperS JSJ,
pubmed-author:VandenhendeFF,
pubmed-author:WallihanR GRG
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
596-602
|
pubmed:dateRevised |
2010-1-13
|
pubmed:meshHeading |
pubmed-meshheading:15196302-Acute Disease,
pubmed-meshheading:15196302-Adult,
pubmed-meshheading:15196302-Analysis of Variance,
pubmed-meshheading:15196302-Chi-Square Distribution,
pubmed-meshheading:15196302-Female,
pubmed-meshheading:15196302-Humans,
pubmed-meshheading:15196302-Isoquinolines,
pubmed-meshheading:15196302-Male,
pubmed-meshheading:15196302-Middle Aged,
pubmed-meshheading:15196302-Migraine Disorders,
pubmed-meshheading:15196302-Receptors, AMPA,
pubmed-meshheading:15196302-Receptors, Kainic Acid,
pubmed-meshheading:15196302-Tetrazoles
|
pubmed:year |
2004
|
pubmed:articleTitle |
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
|
pubmed:affiliation |
Massachusetts General Hospital, Boston, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|